Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 7/20 | 0.41 |
| ▸ | FLT3 | P36888 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371681 | 1.00 | CHEK1 (0.41) | CHEK1FLT3JAK2JAK3KDM1A | |
| SCHEMBL12371637 | 1.00 | CHEK1 (0.41) | CHEK1FLT3JAK2JAK3KDM1A | |
| SCHEMBL13620037 | 0.94 | CHEK1 (0.39) | CHEK1FLT3JAK2JAK3KDM1A | |
| SCHEMBL12371657 | 0.89 | CHEK1 (0.41) | CHEK1FLT3KDM1ASLC6A2SLC6A4 | |
| SCHEMBL12371641 | 0.89 | CHEK1 (0.41) | CHEK1FLT3KDM1ASLC6A2SLC6A4 | |
| SCHEMBL12371650 | 0.89 | CHEK1 (0.41) | CHEK1FLT3KDM1ASLC6A2SLC6A4 | |
| SCHEMBL13608284 | 0.89 | KDM1A (0.43) | CHEK1JAK2JAK3KDM1ADPP4 | |
| SCHEMBL12371714 | 0.87 | KDM1A (0.43) | JAK2JAK3KDM1ASLC6A2SLC6A4 | |
| SCHEMBL13620507 | 0.87 | PIM1 (0.38) | CHEK1FLT3SLC6A2SLC6A4DPP4 | |
| SCHEMBL13620252 | 0.85 | USP1 (0.39) | CHEK1JAK2JAK3KDM1ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989459-B2 | Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one | PHARMACOPEIA, LLC (US) | 2011-08-02 | — | — | US | disclosed |
| WO-2008143674-A1 | PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PRKCE, PRKCH, PRKCQ | CHEK1 520/4885FLT3 1201/4885JAK2 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.